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Abstract
Understanding early immunological events during HIV-1 infection that may set the course of disease
progression is important for identifying correlates of viral control. This study explores the association
of differentiation profiles of HIV-specific and total memory CD8+ T cells with viral set point. A
cohort of 47 HIV-1-infected individuals, with differing viral set points at 12 mo, were recruited during
acute infection. We identified that the magnitude of IFN-γ+ T cell responses at 6 mo postinfection
did not associate with viral set point at 12 mo. A subset of 16 individuals was further studied to
characterize CD8+ T cells for expression patterns of markers for memory differentiation, survival
(CD127), senescence (CD57), and negative regulation (programmed death-1). We show that viral
control and the predicted tempo of HIV disease progression in the first year of infection was
associated with a synchronous differentiation of HIV-specific and total CD8+ memory
subpopulations. At 6–9 mo postinfection, those with low viral set points had a significantly higher
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proportion of early differentiated HIV-specific and total memory CD8+ cells of a central memory
(CD45RO+CD27+CCR7+) and intermediate memory (CD45RO−CD27+CCR7−) phenotype. Those
with high viral set points possessed significantly larger frequencies of effector memory
(CD45RO+CD27−CCR7−) cells. The proportions of memory subsets significantly correlated with
CD38+CD8+ T cells. Thus, it is likely that a high Ag burden resulting in generalized immune
activation may drive differentiation of HIV-specific and total memory CD8+ T cells.
Human immunodeficiency virus 1 infection generally leads to a decline of immune function,
which in the absence of successful antiretroviral therapy results in progression to AIDS.
However, a small group of individuals is able to naturally control viral replication and maintain
high levels of CD4+ cells, known as long-term nonprogressors or elite controllers (1). It is now
well established that virus fitness and/or host genetic background can contribute to the delay
of HIV disease progression (2–5). More controversial is the role of HIV-specific CD4+ and
CD8+ responses in natural viral control. Divergent data show the impact of HIV-specific
CD4+ T cell responses on disease progression (6,7) and, in simian models, there is evidence
that CD8+ T cells may play an important role in the control of viremia (8,9). These data
strengthen the hypothesis that the development of HIV-specific CD8+ T cell responses
contributes to the delay of disease progression in humans and coincides with a reduction in
initial viremia during primary infection (2). Although an inverse relationship has been
described between the proportion of HIV-specific CD8+ T cells and viral load (10), more recent
studies have raised questions about whether the frequency of HIV-specific CD8+ T cells is
associated with viral control (11–13). Furthermore, neither the breadth nor the magnitude of
HIV-specific IFN-γ+ CD8+ T cell responses in chronically infected patients has been shown
to be a marker of viral control (12–15). These latter observations collectively infer that the
quality, more than the quantity, of CD8+ T cell responses might play a role in viral control.
The hypothesis that the quality of CD8+ T cells is important in controlling disease, and would
be important to elicit in vaccine-induced immunity, is supported by data showing that
proliferation and polyfunctional cytokine responses associate with control of HIV (16–18).
Phenotype and function of T cells are integrally linked, and studies have shown that stages of
HIV-specific CD8+ T cell differentiation may be an important qualitative assessment.
Functionally suboptimal HIV-specific cells accumulate in a pre-terminally differentiated stage
(19), and viral control in early and chronic infection is associated with terminally differentiated
HIV-specific effector memory CD8+ cells (14,20). The differentiation status of total CD8+
memory cells may also be important during HIV infection, where recent data have shown that
a late differentiated and aged total CD8+ memory compartment is associated with faster disease
progression (21).
Few studies have investigated the differentiation profiles of CD8+ T cell responses during acute
and early infection, with most data having been collected during chronic infection in cross-
sectional studies. It is well established that plasma viral load at approximately 1 year after
infection, known as viral set point, is a strong predictor of subsequent CD4+ decline rates and
progression to AIDS (22), implying that early events in HIV infection may set the course of
viremia and hence for subsequent disease progression. In SIV infection, massive destruction
of the CD4+ memory T cell compartment occurs in acute infection at mucosal surfaces,
particularly in the gut (23). Additionally, phenotypic defects and increased apoptosis manifest
in the first few weeks after SIV infection (24). As the global vaccine community reflects on
the unsuccessful Ad5 HIV vaccine trial (25), identity of T cell quality and the factors that
influence it during the early stages of infection may be important for vaccine development.
In this study, we examined the association of T cell responses and memory differentiation with
viral set point at 1 year in a subtype C HIV-1 acute infection cohort. We show that total HIV-1-
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specific IFN-γ responses are unrelated to viral control, but a more refined analysis of CD8+ T
cell memory differentiation revealed associations with viral set point.
Materials and Methods
Study subjects
Acute HIV-infected cohort—A longitudinal cohort of acutely HIV-1-infected women were
enrolled as part of the Centre for AIDS Programme of Research in South Africa (CAPRISA)
acute infection study in Durban, South Africa. This study cohort has been described previously
(26,27). The time postinfection was estimated either by a prospective RNA-positive/Ab-
negative measurement or taken as the midpoint between the last Ab-negative test and first Ab-
positive ELISA test. Study participants were followed for 12 mo, and follow-up is ongoing.
Data from events within the first 3–12 mo are reported herein. None of the study individuals
was on antiretroviral therapy during the first year of infection. The University of KwaZulu-
Natal, University of Witwatersrand, and University of Cape Town Research Ethics Committees
approved this study, and all the subjects provided written informed consent for participation
in this study. A total of 47 study participants were analyzed by ELISPOT, and a subset of 16
individuals was analyzed in more depth for HIV-specific memory phenotypes (Table I).
HIV-uninfected cohort—We recruited 15 HIV-uninfected individuals from the Perinatal
HIV Research Unit, Soweto, South Africa, who were the HIV-uninfected partner in an HIV
serodiscordant relationship. Participation in this study was approved by the Human Research
Ethics Committee of the University of the Witwatersrand. After providing informed consent,
participants were tested for HIV with dual HIV rapid tests performed in parallel. All
participants were HIV uninfected by all assays at the enrollment and follow-up visits.
Calculation of viral set point
Viral set point was calculated as the geometric mean of viral load measurements at three time
points at week 52 ± 6 wk postinfection (between 46 and 58 wk) to minimize possible spurious
viral load measurement. In the case where there was an atypical viral load occurring within the
52 ± 6 wk window, defined as a viral load >1 log different from the other measurements within
that period, the datum point was removed and replaced with the next measurement. CAP84
was the only example where a viral load blip at 52 wk was replaced with a measurement beyond
the 6 wk period.
Plasma viral load determination, CD4 T cell counts, and HLA typing
Plasma HIV-1 RNA levels were quantified using the COBAS AMPLICOR HIV-1 monitor test
version 1.5 (Roche Diagnostics). Absolute blood CD4+ and CD8+ T cell counts were measured
using a FACSCalibur flow cytometer and expressed as cells/mm3. HLA typing was performed
as described in Chopera et al. (28).
Synthetic subtype C peptides
A set of 432 synthetic overlapping peptides spanning the entire expressed HIV-1 clade C
proteome corresponding to gene products from the HIV-1 consensus C (Gag, Vif, Vpr, and
Vpu), isolate Du151 (Pol, Nef, Tat, and Rev), and isolate Du179 (gp160 Env) were synthesized
using 9-fluorenyl-methoxycarbonyl chemistry and standard based solid phase techniques
(Natural and Medical Sciences Institute, University of Tubingen, Tubingen, Germany). The
nonconsensus synthesized peptides were based on sequences from isolates used for
manufacture of a clade C vaccine (29). The estimated purity of peptides was >80% as measured
by HPLC and mass spectrometry. Individual peptides were diluted in DMSO (Sigma-Aldrich)
and prepared as previously described (13).
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PBMC were isolated by standard Ficoll-Hypaque density gradient centrifugation (Amershan
Pharmacia) and cryopreserved in 90% heat-activated FBS (Invitrogen) plus 10% DMSO and
stored in liquid nitrogen until needed. Frozen PBMC were thawed and rested in RPMI 1640
(Invitrogen) containing 10% heat-inactivated FBS and 50 U gentamicin (Invitrogen) at 37°C
and 5% CO2 for 18 h before use in ELISPOT and intracellular cytokine staining assays.
IFN-γ ELISPOT assay
HIV-1-specific T cell responses were quantified by the IFN-γ ELISPOT assay using the set of
overlapping peptides arranged in a pool-matrix format as previously described (13). Briefly,
PBMC were plated at 1 × 105 cells/ml with peptides at a concentration of 2 µg/ml in 96-well
polyvinylidene difluoride plates (Millipore) that had been coated with 5 µg/ml anti-IFN-γ mAb,
1-DIK (Mabtech) overnight at 4°C. PHA (Calbiochem) stimulation at 4 µg/ml was used as
positive control, and no peptide stimulation (medium alone) was used as negative control. As
part of an ongoing quality assurance program, thawed PBMC that had been tested previously
for responses to a pool of optimal peptides corresponding to CMV, EBV, and flu viruses were
included on the same plate as a positive quality control sample for assay consistency. Plates
were incubated overnight at 37°C, 5% CO2 and developed as previously described (13).
Individual spots were counted with an automated ImmunoSpot plate reader (Cellular
Technology) and expressed as spot-forming cells per million PBMC. Responses were initially
evaluated by reacting PBMC with peptides arranged in a pool-matrix format and then followed
with a second ELISPOT assay to confirm positive responses at the single-peptide level in
triplicate. The following criteria were used to define positive responses: 1) reactivity to peptide
pools were ≥67 spot-forming cells per 106 PBMC after background subtraction and at least
three times greater than the mean background activity, and 2) a matching peptide in the matrix
pool array.
Surface phenotypic and intracellular cytokine staining using flow cytometry
Flow cytometric detection of phenotypic and functional markers was performed essentially as
described in (30). The following Abs and fluorophores were used: CD3-Cy7-allophycocyanin,
CD3-Cy7-PE, IFN-γ-FITC, CD38-allophycocyanin (all BD Pharmingen), CD4-Cy5.5-PE
(Caltag Laboratories), CD27-Cy5-PE, CD45RO-Texas Red-PE, CD127-PE (all Beckman
Coulter), programmed death-1 (PD-1)4-biotin (R&D Systems), CD57-quantum dot (QD) 545,
CD8-QD705, streptavidin-QD655, CD14-Pacific Blue, and CD19-Pacific Blue, conjugated
according to standard protocols. Detailed dot plots of PD-1 labeling are provided in
supplemental Fig. S2.5 Unconjugated Abs were from BD Pharmingen. All Abs were pretitered
to optimal concentrations. Briefly, PBMC were stimulated with anti-CD28 and anti-CD49d (1
µg/ml) either alone or together with one to four peptide pools (Gag, Pol, Nef, and Env) at 1
µg/ml for 6 h in the presence of brefeldin A (10 µg/ml; Sigma-Aldrich). Table I shows the
selection of peptide pools used to stimulate cells from a subset of 16 participants of the study.
Cells were then stained with CCR7 for 10 min at 37°C, followed by surface staining with CD4,
CD8, CD45RO, CD27, CD127, CD57, PD-1, CD14, and CD19 Abs, as well as violet amine
reactive dye (Vivid; Molecular Probes). This was followed by incubation with streptavidin-
Qdot655 for 10 min, and cells were then fixed and permeabilized using Cytofix/Cytoperm
buffer (BD Biosciences) and stained intracellularly with CD3 and IFN-γ. For examining
immune activation, unstimulated PBMC were surface stained with a separate panel that
included CD3, CD8, CD27, CD45RO, CD38, CD19, and the viability dye Aqua Blue
(Molecular Probes). After washing, cells were resuspended in 1% paraformaldeyde (Electron
4Abbreviations used in this paper: PD-1, programmed death 1; TCM, central memory T cell; TEff, effector T cell; TEM, effector memory
T cell; TInt, intermediate memory T cell; TNaive, naive T cell; TTM, transitional memory T cell.5The online version of this article contains supplemental material.
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Microscopy Solutions). Approximately 500,000 events were acquired per sample on an LSRII
flow cytometer (BD Biosciences), and analysis was performed using FlowJo v8.5.3 (Tree Star).
Dead cells (Vivid+ or Aqua Blue+), monocytes (CD14+), and B cells (CD19+) were excluded
from the analysis. A time gate was first evaluated, and then cells were gated on singlets, live
CD3+, CD8+, CD8+ memory, and then either IFN-γ and combinations of markers, or CD38+
cells for measuring immune activation. The gating strategy is provided in supplemental Fig.
S3. Memory subsets and CD38+ cells are expressed as a percentage of total CD8+ memory
cells (i.e., excluding naive CD45RO−CCR7+CD27+CD8+ cells, or in the case of the activation
panel, excluding CD45RO−CD27+ CD8+ cells). A positive cytokine response was defined as
at least twice background (no Ag, only costimulatory Abs), >0.05% after subtraction of
background, and at least 50 events. The latter criterion was introduced so as to minimize the
possibility of error due to a low number of events when further subdividing these cells into the
five memory subsets. All data points for IFN-γ-specific responses after Fig. 1 represent positive
peptide pool responses; that is, negative responses were excluded from subsequent analysis in
the IFN-γ+ compartment.
Statistical analysis
Statistical analysis and graphical presentation were performed using InStat and GraphPad
Prism version 3.0 software. Data are expressed as median values with interquartile ranges and
analyzed by the use of nonparametric statistics. Statistical analysis of significance was
calculated using either Mann-Whitney or Kruskal-Wallis ANOVA using Dunn’s test for
multiple comparisons. All tests were two-tailed, and a value of p < 0.05 was considered
statistically significant. The relationship between proportions of memory subpopulations and
plasma viral load set point (in RNA copies/ml) was analyzed using Spearman rank correlations.
Results
HIV-specific IFN-γ+ T cell responses at 6 mo postinfection do not associate with viral set
point at 12 mo
We first sought to investigate whether IFN-γ-specific T cell responses measured at 6 mo
postinfection, using the ELISPOT assay, associated with viral set point at 12 mo after subtype
C infection. HIV-specific IFN-γ+ T cell responses were measured in 47 individuals with a range
of viral set point levels at 12 mo, from 400 to 1,750,000 RNA copies/ml. Fig. 1A shows no
significant association between the magnitude of HIV-specific T cell responses to Gag, Pol,
Nef, or Env at 6 mo postinfection and viral set point at 12 mo. Interestingly, the lack of
association of responses with set point underlie the notion that possible important T cell
responses, especially to Gag, may only emerge later during infection (31). We have also shown
recently that the total magnitude of the IFN-γ+ response made earlier at 3 mo postinfection had
very poor predictive power with viral set point (32). Similarly, when measuring total IFN-γ+
responses using intracellular cytokine staining in a subgroup of 16 individuals, shown in Table
I, we identified that the major IFN-γ+ responses were from CD8+ T cells and that the proportion
of these cells poorly associated with viral set point (Fig. 1B). These data demonstrate that early
HIV-specific IFN-γ+ T cell responses can be of considerable magnitude but appear to have no
bearing on viremia during the first year of infection.
Defining CD8+ T cell differentiation profiles
To refine the analysis further, we used polychromatic flow cytometry to investigate in greater
detail the level of total and IFN-γ+ HIV-specific CD8+ T cell memory differentiation in the 16
individuals at a median time postinfection of 31 wk. The subgroup of 16 individuals did not
differ significantly from the larger group of 47 individuals with respect to time from infection
at recruitment, viral load, or CD4 count at 12 mo (Table I). Furthermore, there was no evidence
of particular HLA allele frequencies being over- or under-represented in the subgroup
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compared with the larger group of individuals (data not shown). In this study we present our
findings on the CD8+ memory compartment, and focus elsewhere on CD4+ memory in early
infection (W. A. Burgers et al., manuscript in preparation). Fig. 2A shows representative dot
plots of total CD8+ T cell subpopulations based on differential expression of CD45RO, CD27
and CCR7, where naive T cells (TNaive) along with five distinct memory populations can be
distinguished, namely central memory cells (TCM), transitional memory cells (TTM), effector
memory cells (TEM), cells that we have termed intermediate memory (TInt), and effector
(TEff) cells. When we evaluated the proportion of these subsets in HIV-uninfected and HIV-
infected individuals, no statistically significant differences were observed, although there was
a trend toward a greater proportion of TTM and fewer TEff in HIV-infected individuals (Fig.
2B). Further characterization of the differentiation status of these memory subsets in HIV-
infected individuals was made by assessing expression of CD127, the IL-7 receptor associated
with long-term survival of cells (33); CD57, a marker of replicative senescence (34); and PD-1,
a negative regulator of activation that has recently been linked with immune dysfunction
(35–37). Most TNaive and TCM cells expressed CD127 (~90% and 77% respectively, Fig.
2C), while very few of these cells expressed CD57 (<3%). At the other extreme, TEff were
characterized by the lowest expression of CD127 (by ~10% of these cells, Fig. 2C) and the
highest expression of CD57 (by ~50%). Interestingly, PD-1 displayed an unexpected
expression pattern, with more TCM and TTM expressing PD-1 compared with TEff. This has
also been found by others (38), although we observed a higher proportion of TCM that expressed
PD-1. Note that frequencies of CD127, CD57, and PD-1 expression on TEM were highly
heterogeneous between individuals. Since CD127 characterizes long-lived cells and CD57
expression defines replicative senescence, we ranked the CD8+ T cell memory subpopulations
based on the predicted ability to survive and proliferate from highest to lowest:
TNaive→TCM→TTM→TInt→TEM→TEff (Fig. 2C, right panel, and D).
Distribution of HIV-1-specific and total CD8+ memory cell populations
We next assessed the differentiation phenotypes of both HIV-specific and total CD8+ T cells,
with the former consisting of discernible IFN-γ responses to Gag, Pol, Nef, or Env peptide
pools (Table I). Representative density and overlay dot plots, showing the phenotype of total
and IFN-γ+CD8+ T cells, at 6–9 mo postinfection in individuals with low and high viral set
points are shown in Fig. 3A. Within the CD45RO+ compartment (allowing us to detect TCM,
TTM, and TEM), total and HIV-specific CD8+ TCM were more abundant in individuals with
low viral set point. Conversely, individuals with high viral set point were characterized by a
higher frequency of TEM in both total and HIV-specific CD8+ T cells. Within the CD45RO−
compartment (allowing us to detect TInt and TEff), the IFN-γ+CD8+ TInt memory subset was
more abundant in individuals with low viral set point. There was variability in TEff frequencies
in individuals with high viral set point, and these cells were not always observed in this
compartment. These plots represent our main finding that lower set point at 12 mo postinfection
was associated with a pool of less differentiated CD8+ memory T cells in both total and HIV-
specific cells at 6–9 mo postinfection. Although there was a large level of heterogeneity
between total CD8+ memory cells and IFN-γ-specific cells, the two populations tended to
mirror each other, with the exception that there were significantly fewer HIV-specific TEff
(p < 0.001), and a there was a trend toward a greater number of HIV-specific TTM compared
with total memory cells (Fig. 3B).
Differentiation status of HIV-specific and total CD8+ T cells associates with viral set point
To further investigate the relationship between CD8+ memory subsets and viral set point, we
correlated TCM, TTM, TInt, TEM, and TEff memory populations at 6–9 mo with viral set point
at 12 mo. Fig. 4A shows that the frequencies of total TCM and TInt inversely correlated with
viral set point (r = −0.68, p = 0.003 and r = −0.52, p = 0.036, respectively), while the frequency
of total CD8+ TEM positively associated with viral set point (r = 0.63, p = 0.009). No significant
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relationships were found between viral set point and TTM and TEff cell populations (data not
shown). We also examined the frequencies of TNaive cells in the total CD8+ T cell population
and found that there was a significant negative association with viral set point (p = 0.01, r =
−0.59, data not shown). To take into account variation in CD8+ counts among study subjects,
we also performed correlations between the absolute number of cells in each memory
subpopulation (based on absolute CD8+ cells/µl) and viral set point. The absolute number of
TCM, TInt, and TEM cells reflected the relationships found for percentage of memory cells (r
= −0.6, p = 0.014; r = −0.52, p = 0.03; and r = 0.49, p = 0.05, respectively; supplemental Fig.
S1). We next assessed the relationship between HIV-1-specific IFN-γ+CD8+ TCM, TTM, TInt,
TEM, and TEff profiles with viral set point and found that there was a significant negative
association between TCM and TInt with set point (r = −0.54, p = 0.002 and r = −0.47, p = 0.008,
respectively; Fig. 4B). Additionally, the proportion of IFN-γ+CD8+ T cells that possessed a
TEM phenotype positively correlated with viral set point (r = 0.58, p = 0.0009; Fig. 4B). As in
total CD8+ T cells, no correlations were observed between the proportion of TTM and TEff in
HIV-specific cells and viral set point (data not shown). Further analyses showed significant
positive correlations between total and HIV-specific TCM, TInt, and TEM (r = 0.56, p = 0.0016;
r = 0.6, p = 0.0005; and r = 0.62, p = 0.0004, respectively; Fig. 4C), revealing that there was
a synchronous differentiation profile of HIV-specific and total CD8+ T cells.
CD8+ T cell memory differentiation associates with immune activation
When we examined the relationship of differentiation profiles with concurrent viral load (at
the time of analysis), we found a significant inverse correlation between HIV-specific TCM
and a positive correlation of TEM with viral load (r = −0.41, p = 0.02 and r = 0.47, p = 0.009,
respectively). The strength of these correlations did not hold when associating total memory
CD8+ phenotypes with concurrent viral load (TCM, r = −0.47, p = 0.067; TEM, r = 0.39, p =
0.134). This would suggest that viremia exclusively drives HIV-specific CD8+ T cell
differentiation, but not necessarily total memory differentiation. To examine whether the
overall level of T cell activation was possibly related to memory differentiation, we examined
CD38 surface expression on total CD8+ memory T cells using a separate activation phenotype
Ab staining panel. It is well known that CD38 is a marker of generalized immune activation,
and expression on CD8+ T cells is a strong indicator of disease progression (39). We found an
inverse correlation between proportions of total CD8+ TCM and a positive correlation for total
CD8+ TEM with CD38+CD8+ total memory cells (r = −0.53, p = 0.036 and r = 0.66, p = 0.005;
Fig. 5A). This relationship also held true for HIV-specific cells (TCM, r = −0.44, p = 0.016;
TEM, r = 0.72, p < 0.0001; Fig. 5B), and the level of immune activation correlated significantly
with viral set point (r = 0.63, p = 0.008). These data infer that immune activation is possibly
a strong driver of memory differentiation. Thus far, we have shown that the predominance of
a particular CD8+ memory subset significantly associates with viral set point. High set point
at 12 mo is preceded by an imbalance of the TNaive→TCM→TTM→TInt→TEM→TEff profile
within the memory CD8+ T cell compartment, with a shift toward a more differentiated profile
in both total and HIV-specific IFN-γ+CD8+ T cells. These imbalances are strongly associated
with varying levels of immune activation as measured by CD38 surface expression.
Survival and differentiation phenotypes correlate with viral set point
To investigate the predicted survival capacity of HIV-specific CD8+ T cells, we examined the
expression of CD127 and CD57 on IFN-γ+CD8+ T cells. Representative CD127 and CD57
staining profiles for individuals with low or high viral set points are shown in Fig. 6A, where
density plots represent total memory subsets overlayed with HIV-specific responses. From
these examples it was apparent that there were fewer CD127+ and more CD57+ cells within
the total memory population found in individuals with a high viral set point (Fig. 6A), while
individuals with a low viral set point had greater frequencies of CD127+ HIV-specific IFN-γ-
producing cells. There was a significant negative association between CD127 expression in
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total memory and HIV-specific CD8+ T cells with viral set point (r = −0.64, p = 0.0067 and
r = −0.60, p = 0.0005, respectively; Fig. 6B), suggesting that HIV-specific cells from
individuals able to control viremia have a better ability to be homeostatically maintained
through the IL-7 survival pathway. The expression frequencies of CD57 showed a significant
positive correlation with viral set point in the total CD8+ memory compartment (r = 0.52, p =
0.036), but this was not mirrored in HIV-specific IFN-γ+ cells. For PD-1 expression, neither
the percentage of cells nor the levels of PD-1 (as measured by median fluorescent intensity)
were significantly associated with viral set point (data not shown). Note that expression levels
of CD57 on HIV-specific cells were marginal compared with CD57 expression on total
memory CD8+ T cells (median, ~5% and 25%, respectively). Low expression of CD57 on
HIV-specific cells has previously been reported (40).
To summarize, when we compared the distribution of
TNaive→TCM→TTM→TInt→TEM→TEff subsets in HIV-specific and total memory CD8+ T
cells in individuals with low vs high viral set points, we observed that a high set point was
preceded by a higher frequency of effector memory cells and lower frequencies of central and
intermediate memory cells (Fig. 7). Conversely, a low set point at 12 mo was preceded by a
larger pool of less differentiated central and intermediate CD8+ T cell memory phenotypes
(Fig. 7). These data suggest that pools of central and intermediate memory CD8+ T cells
accumulate in the peripheral blood of individuals who are able to later control viral replication
at 12 mo.
Discussion
In this study we have investigated features of the early CD8+ T cell response that mediate viral
control within the first year of infection in a subtype C HIV-1 acute infection cohort (26). We
have shown that the magnitude of HIV-1-specific IFN-γ+ T cell responses to Gag, Pol, Env,
and Nef during early infection were not associated with viral set point at 12 mo. When we
examined differentiation phenotypes of both total and HIV-specific CD8+ T cells, we found
that a less differentiated profile correlated with a lower viral set point, while a more
differentiated profile correlated with a higher viral set point. Unraveling relationships in early
HIV infection between T cell differentiation, immune activation, viral control, and disease
progression that may influence this skewing is important to advance our understanding of HIV
pathogenesis.
T cells are composed of different memory subsets, or maturational stages, which are
characterized by differential homing capacities, survival times, and functional abilities (41,
42). According to our present understanding, TNaive and TCM preferentially home to lymph
nodes, while TEM and TEff subsets, lacking CCR7 expression, are localized in tissues.
Phenotype and function are linked, where TCM are endowed with a better proliferation
potential, being able to self-renew, compared with TEM and TEff, which are considered
terminally differentiated cells and die upon restimulation (43,44). TEM are endowed with ready
effector functions, and ex vivo human TEM are characterized by higher levels of perforin and
granzyme B expression and display greater cytotoxic abilities compared with TCM (45). In
mice, however, Barber et al. showed that upon reactivation, TCM and TEM were equally
efficient at cytotoxic killing in vivo (46). While TCM cells express little perforin and granzyme,
they can acquire these functions rapidly upon secondary encounter with Ag. Thus, TCM may
be more effective at mediating protective immunity by virtue of their ability to proliferate,
which may be particularly important for persisting infections. Thus, according to the functional
characteristics of TCM, an early accumulation of these cells preceding low viral set point
suggests a role for these cells in viral control. We could hypothesize therefore that long-lived
TCM and TInt found in individuals with low set points may reflect a greater ability to proliferate
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and subsequently control viremia over time. The alternative possibility is that differentiation
status may simply reflect antigenic burden and levels of immune activation.
One of the most intriguing findings in our study was the synchronous differentiation profile of
HIV-specific and total CD8+ memory cells. This begs the question: What factors may shape
the immune system in the first year of infection? The most obvious candidate is HIV itself,
providing persistent Ag stimulation for T cells. Reactivation of latent CMV, EBV, and other
co-viral infections may also provide a plethora of specific antigenic stimuli within the CD8+
memory compartment (47). Additionally, indirect stimulation of memory cells by a highly
activated immune system may also explain the effects on the total CD8+ memory compartment.
Immune activation can be caused by TLR ligands within HIV RNA (48) or by microbial
translocation from the gut (49). The degree to which all of these factors contribute to the early
skewing of the total CD8+ memory compartment is not known; however, the link between
CD8+ memory differentiation and immune activation has previously been proposed (40).
Results from this study suggest that the highly differentiated status of CD8+ T cells is a
consequence of persistent immune activation, which affects not only HIV-specific cells but all
memory cells, and could therefore lead to extensive cell division and differentiation, resulting
in premature exhaustion of cell functions. Our data support this, where we show that higher
immune activation levels in bulk CD8+ memory cells, as measured by CD38+ expression, are
associated with fewer TCM and more TEM. There is also the possibility that early skewing of
HIV-specific CD8+ memory cells is related to the differentiation status of the memory
compartment before HIV infection. Nonetheless, our data suggest that the establishment of a
“protective” immune response could, in part, rely on the generation and maintenance of early
differentiated cells endowed with greater self-renewal and survival abilities.
The use of CD27 staining in combination with CCR7 allowed us to define an intermediate
population of CD8+ T memory cells (CD45RO−CD27+CCR7−), which we termed “TInt”.
These cells have been previously noted in studies examining CD8+ T cell responses to vaccinia
virus and CMV (50,51). Our data show that, in addition to TCM, the proportions of TInt in both
total and HIV-specific memory CD8+ T cells were inversely associated with viral set point.
We also identified the TInt population in total CD8+ memory cells in HIV-uninfected
individuals at similar proportions, where they constitute a sizeable proportion of the total
CD8+ memory compartment. They appear distinct from TEff, with few TInt cells expressing
CD57, and the proportion of cells expressing CD127 is intermediate between TCM and TEM.
This suggests that these cells represent a memory subset in early differentiation, and that they
may be endowed with proliferation abilities and be sensitive to IL-7. Indeed, Wills et al. (51)
showed that these cells can proliferate strongly. Further investigations are needed to define the
functional capacities of this subset and to establish its relationship to other memory subsets in
a maturational pathway.
Our data are in apparent contrast to two recent studies that show that late differentiated HIV-
specific CD8+ T cells (CD45RA+ CCR7− cells, termed terminally differentiated effector cells
or TEMRA in these studies) were associated with viral control in HIV infection (14,20).
Chronically infected individuals controlling viral load had a greater number of these cells than
progressors (14), and in early infection, their presence was associated with lower viral set points
(20). In these studies memory subsets were discriminated on the basis of CD45RA and CCR7
expression, so terminally differentiated cells were equivalent to our combined TInt and TEff
subsets, since we used CD27 to further define these subpopulations. Indeed, if we group these
subsets together, we reach a similar conclusion in our study, with HIV-specific CD45RO−
CCR7−CD8+ cells correlating inversely with viral set point (data not shown). However, it is
clear that the CD45RO−(RA+)CCR7− subset is highly heterogeneous in terms of CD127 and
CD57 expression, and additional markers such as CD27 aid in distinguishing between cells
that may be functionally diverse.
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We further characterized memory populations on the basis of CD127, CD57, and PD-1
expression. A paucity of CD127-expressing cells has been observed in chronic HIV infection
and is related to persistent viremia (52,53). Indeed, it has been shown that the accumulation of
CD8+CD127− cells correlates with higher HIV viral load and lower CD4 counts (54). In line
with these findings, we show in early HIV infection that CD127 expression was higher on
HIV-specific IFN-γ+ cells in individuals naturally controlling viral replication compared with
individuals possessing high viral set points, consistent with our observations of preserved early
memory subsets. With regard to CD57 expression, although there was a trend toward higher
CD57 expression on CD8+ T cells in those with high set points, the overall expression of CD57
was very low (<10%). The modest expression of CD57 on these cells, despite their late
differentiated phenotype, could be due to the rapid disappearance of the HIV-specific
CD57+ cells, in keeping with their high sensitivity to activation-induced cell death (34). We
also did not find any significant association between PD-1 expression on total and HIV-specific
IFN-γ+CD8+ T cells and viral control. Surprisingly, when analyzing total memory subsets, we
observed high frequencies of PD-1+ cells in early and intermediate differentiated subsets (i.e.,
TCM and TInt), cells that were associated with better viral control at 1 year. This is in apparent
conflict with evidence linking increased PD-1 expression to immune dysfunction, higher viral
loads, and lower CD4 counts in chronic HIV infection (36,37,55). Our observations are in
agreement with Sauce et al. (38), who found that PD-1 expression is higher on less
differentiated than terminally differentiated memory subsets, where these PD-1+ cells remain
fully functional, suggesting that PD-1 does not solely play a role in T cell exhaustion but could
be implicated in T cell differentiation and/or activation. Further investigations are required to
establish the precise role played by PD-1 in balancing stimulatory signals with inhibitory
signals that maintain homeostasis of differentiated cells. Moreover, PD-1 expression is up-
regulated in concert with markers of immune activation, so high levels of PD-1 in chronic HIV
infection may be linked to the generalized immune activation, which is a hallmark of
progressive disease (56). Other recent studies also support a regulatory role for PD-1 in memory
cell differentiation (57,58).
Overall, we have shown that viral control and the tempo of HIV disease progression in the first
year of infection are linked to the presence of particular CD8+ memory subpopulations.
Phenotypes associated with more differentiated memory cells accumulate by 6–9 mo in
individuals with higher viral set points at 12 mo and are associated with a higher CD8+ T cell
activation status. Conversely, the presence of less differentiated and longer lived CD8+ cells
correlates with lower viral set point at 1 year after infection and is associated with a lower cell
activation status. In conclusion, the level of immune activation may be a central driver
underlying memory cell differentiation, where we hypothesize that persistently elevated
activation signals push memory cell differentiation to TEff and senescence. What is cause and
effect between viral load, memory differentiation, and immune activation remains the vexing
issue.
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Correlation of the magnitude of HIV-specific IFN-γ+ CD8+ T cell responses at 6 mo
postinfection measured by ELISPOT or intracellular cytokine staining flow cytometry with
viral set point at 12 mo postinfection. A, IFN-γ+ T cell responses were determined using the
ELISPOT assay against pools of peptides corresponding to regions of the HIV-1 subtype C
proteome in 47 individuals recruited during acute HIV infection. Each dot represents the
cumulative sum of positive responses within each protein region (Gag, Pol, Env, and Nef) per
individual at 6 mo postinfection. Magnitudes of responses were correlated with viral set point
at 12 mo postinfection. B, IFN-γ+ CD8+ T cell responses at 6 mo postinfection were assessed
in a subgroup of 16 study subjects by intracellular cytokine staining to detect responses toward
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Gag, Pol, Env, and Nef peptide pools. The percentage of IFN-γ+CD8+ T cells per individual
was correlated with the viral set point at 12 mo postinfection. Statistical associations were
determined using two-tailed nonparametric Spearman rank correlation.
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Representation and definition of CD8+ T cell memory subpopulations. Expression of
differentiation markers including CD45RO, CD27, CCR7, CD57, PD-1, and CD127 were
analyzed on total CD8+ T cells at 6–9 mo postinfection using flow cytometry. Using these
markers, we were able to discriminate six different subsets: central memory (TCM,
CD45RO+CD27+CCR7+), transitional memory (TTM, CD45RO+ CD27+CCR7−), effector
memory (TEM, CD45RO+CD27−CCR7−), naive (TNaive, CD45RO−CD27+CCR7+),
intermediate (TInt, CD45RO−CD27dim CCR7−), and effector (TEff, CD45RO−CD27−CCR7−).
A, Representative flow plots of CD45RO, CD27, and CCR7 profiles of total CD8+ T cells and
the gating strategy for detection of TCM, TEM, TTM, TNaive, TInt, and TEff. B, Comparison of
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memory subset distribution in HIV-uninfected (n = 15) and HIV-infected individuals (n = 16).
C, Percentage expression of CD127, CD57, and PD-1 in TCM, TEM, TTM, TNaive, TInt, and
TEff. Each datum point represents an HIV-positive individual. Proportional differences in
expression of CD27, CCR7, CD45RO, CD127, CD57, and PD-1 are shown as heat maps, based
on the mean percentage expression within the different CD8+ T cell subpopulations. D,
Representative flow plots for CD57/CD127 and CD127/PD-1 staining in TNaive, TCM, TEM,
TTM, TInt, and TEff CD8+ T cells subsets.
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Distribution of CD8+ memory subpopulations between total memory cells and HIV-specific
cells. PBMC from HIV-infected individuals (n = 16) at 6–9 mo postinfection were stimulated
with Gag, Nef, Pol, and Env peptide pools and the frequency of CD8+ memory subsets was
quantified from IFN-γ-producing T cells (IFN-γ+) and total memory CD8+ T cells (total
memory). A, Representative density and overlay dot plots of memory subsets in total CD8+ T
cells (density) and Gag-specific IFN-γ+ CD8+ T cells (red dots) defined according to CD45RO,
CD27, and CCR7 expression levels. Left panels, CD45RO+ memory CD8+ T cells at 6–9 mo
postinfection in three individuals (CAP084, CAP228, and CAP045) having a low viral set point
(SP) at 12 mo postinfection and three individuals (CAP256, CAP174, and CAP210) with high
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viral set point at 12 mo postinfection. Right panels, CD45RO− memory CD8+ T cells in low
and high viral set point individuals. Numbers in the quadrants correspond to the proportion of
each memory subset in total memory CD8+ T cells (in black), expressed as a percentage of
total memory cells, while the proportion of IFN-γ+CD8+ T cells are in red. Patient identification
numbers and viral set point (SP) at 12 mo are shown. B, TCM, TTM, TInt, TEM, and TEff memory
subsets expressed as a percentage of total memory cells. For total memory, each datum point
represents a study individual, and for IFN-γ+ cells, each datum point represents a positive HIV-
specific response. The median is shown as a horizontal bar. Statistical comparisons were
performed using Krukal-Wallis ANOVA and multiple comparisons using Dunn’s test.
Burgers et al. Page 20














Correlations of the percentage of TCM, TInt, and TEM at 6–9 mo postinfection with viral set
point at 12 mo postinfection: (A) in total CD8+ memory T cells, (B) in HIV-specific IFN-
γ+CD8+ memory T cells, and (C) between total and HIV-specific CD8+ memory T cells. For
total memory, each datum point represents a study individual, and for IFN-γ+ cells, each datum
point represents a positive HIV-specific response. Statistical associations were determined
using two-tailed nonparametric Spearman rank correlation.
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Relationship between immune activation and memory differentiation. Correlation of the
percentage of CD38+ memory CD8+ T cells with TCM and TEM at 6–9 mo postinfection: in
(A) total CD8+ memory T cells and in (B) HIV-specific IFN-γ+CD8+ memory T cells. Statistical
associations were determined using two-tailed nonparametric Spearman rank correlation.
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Phenotypic expression of CD57 and CD127 on total memory and HIV-specific CD8+ memory
subpopulations. A, Representative CD127 vs CD57 density plots depicting total memory (gray)
with overlayed IFN-γ+CD8+ T cells (red dots) in two study individuals with a low 12 mo viral
set point (left panels) and two individuals with a high viral set point (right panels). Numbers
in the quadrants represent the percentage of CD127+CD57−, CD127+CD57+, CD127+
CD57−, and CD127−CD57+ cells in total memory CD8+ T cells (in black) and in IFN-
γ+CD8+ T cells (in red). Patient identification numbers and viral set point (SP) at 12 mo are
shown. B, Correlation of the percentage of CD127+ and CD57+ cells in total memory (left
panel) and IFN-γ+CD8+ T cells (right panel) at 6–9 mo postinfection with viral set point at 12
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mo postinfection. Statistical associations were determined using two-tailed nonparametric
Spearman rank correlation.
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Balance of memory CD8+ T cell populations in HIV-positive individuals with low or high viral
set point at 12 mo postinfection. Representation of the proportion of CD8+ T cells memory
subpopulations (TCM, TEM, TTM, TInt, and TEff) in total memory and HIV-specific CD8+ T
cells at 6–9 mo postinfection in HIV-infected individuals with low (n = 4) or high (n = 4) viral
set point. Asterisks indicate significant differences between low and high viral set point
individuals (*, p < 0.05; **, p < 0.005).
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